Colorectal Cancer Screening for Older Adults
Overview of the Study
Colorectal cancer (CRC) is the second most deadly cancer worldwide. As such, the need for resilient colorectal cancer screening (CRCS) is increasingly becoming more important to reduce complications due to delays in care. However, the realistic participation target remains unelucidated.
This research aims to identify the lowest acceptable participation rate in CRCS with regard to vulnerable older populations who require immediate intervention. Colorectal cancer screening requires resilience as early detection is critical to long term outcomes. This study revealed that, for vulnerable older populations, participation rates ≥38% for the primary screening and ≥ 85% for the follow-up should be achieved to maintain early detection of colorectal cancer.
Successful implementation of this study can help resilient target setting by serving as a foundation for balancing the resources between cancer screening and pandemic measures, or a minimum target for shifting to a stool test-focused program.
Colorectal cancer screening (CRCS)
The pandemic-related shutdowns disrupted ongoing CRCS. Statistics show that screening rates declined from 28% to 100%. The impacts appeared greater for regions where screening programs were paused for long periods of time, and for pandemic-vulnerable segments of society, such as older populations. Given that colorectal cancer (CRC) is the second most deadly cancer worldwide, it is vital to create a pandemic-resilient CRCS, especially for vulnerable populations.
The researchers clarified the lowest acceptable limit for the screening rate. It was expected that the lowest limit screening rate indicates what percentage of screening rate should be achieved (to what extent screening rate can be compromised) during the pandemic. The lowest limit for screening rate by fecal immunochemical test (FIT) can also suggest what level of screening rate is necessary for shifting to a FIT-focused program effectively.
In addition, the researchers recognized that the older population is the segment requiring urgent intervention. The reasons are the following:
- Healthcare access is disproportionately affected in this population
- CRCS backlogs for those aged ≥70 years increased considerably during the 2020 pandemic
- Delayed CRC diagnosis is more critical in them
- The importance of cancer prevention is still sufficiently focused in this group
- The impacts on CRC incidence are substantial in this age group
This nationwide cross-sectional study included 80,946 inpatients aged 70–85 years who were first diagnosed with colorectal cancer (CRC) after 70 years of age, between April 1, 2014, and March 31, 2019, in Japan. To evaluate the association between area-level CRCS participation rate and individual early CRC detection, a multilevel logistic regression model was constructed. The mandatorily implemented screening rates were converted to the total screening rate equivalents (TSREs), which reflect the remaining contributions of voluntarily provided screenings.
The researchers used an anonymized dataset extracted from the Diagnosis Procedure Combination/Per-Diem Payment System (DPC/PDPS) database, a medical claim-based national database.
The DPC/PDPS database includes information on individual patients, such as age, sex, International Statistical Classification of Diseases, Tenth Revision (ICD-10) code, stage at diagnosis, medical procedures, insurance type, and postal code.
As of April 1, 2018, the DPC/PDPS covered 1730 hospitals and 488,563 beds, and Japan’s acute inpatients were regarded as almost fully accommodated. This study included 1165 DPC/PDPS members and 98 nonmember hospitals.
A total of 174,469 inpatients were identified through DPC/PDPS dataset who (1) were aged 70–85 years;12 (2) completed hospitalization between April 1, 2014, and March 31, 2019; (3) were first diagnosed with CRC (ICD10 codes: C18.0–C18.9 and C26.0 for colon, and C19.9 and C20.9 for rectal cancer21); (4) had not been hospitalized for cancers until 70 years of age as an acute admission; and (5) not partaking in a clinical trial.
Excluded patients were those with (1) unavailable data for body mass index (BMI) and Brinkman index (BI); (2) unmatched municipal codes and missing screening or follow-up rate; and (3) were from municipalities with small population sizes (the number of follow-up candidates by sex and age group was estimated to be <30). Consequently, 80,946 records (468 municipalities or administrative districts22) were extracted for our main analyses.
The primary outcome of this study was early detection of CRC during stages 0–I. This was mainly because the detection of CRC during stages 0–I, where the survival rate remains over 90% (91.6–94%), is crucial for mortality reduction. Besides, as the probability of main lymph node metastases remains <1% for these earlier stages, first-line therapies (endoscopic or surgical treatment) are less invasive and hence, less costly. Cancer staging was based on the Japanese Classification of Colorectal, Appendiceal, and Anal Carcinoma developed consistent with the Union Internationale Contre le Cancer staging system.
Early detections during stages 0–I were significantly observed when the primary screening rate was ≥38% (TSRE) and the combined follow-up rate was ≥85%. For early detection during Tis–T1, a primary screening rate of≥ 38% (TSRE) and a combined follow-up rate of≥ 90% were necessary. For follow-up rates ≥70% or ≥75%, there were cases where missed detection of Tis–T1 was observed.
The results indicate that, even during the pandemic, CRCS should achieve a primary screening rate of 38% and a follow-up rate of 85% for vulnerable older populations. These values, lower than the current desirable rates, suggest the maximum possible compromise in balancing the resources between cancer screening efforts and outcome measures. Moreover, they also indicate the minimum target for shifting to a fecal immunochemical test-focused program. Further explorations with varied CRCS settings are necessary for verification.
By defining the older population as a segment requiring urgent intervention in the ongoing pandemic, the researchers reported here that the screening rate ≥ 38% and combined follow-up rate ≥ 85% are necessary to sustain the area-level early detection of CRC (stage 0–I). Below these threshold values, the two-step CRCS may not perform as expected. Therefore, importantly, it is suggested that the screening rate of 38% and combined follow-up rate of 85% be regarded as the lowest acceptable limits to be achieved, even during pandemics.
The lowest acceptable limits present a reasonable fit with the currently set target rates. The primary screening rate of 38% was found to be moderately lower than the desired rate in Japan (50%), and considerably lower than the EU and Canadian desirable levels (65% and 60%, respectively).34, 35 An 85% follow-up rate lies below the common desirable level in Japan and the EU (90%). These relationships imply that the lowest acceptable limits can help pandemic-resilient target setting because the participation targets can be made more flexible with a clear, maximum compromise of 12–27% for the primary screening rate and 5% for the combined follow-up rate to optimize balanced pandemic measures.
Unexpected issues were observed in comparison with the current screening rates. The threshold screening rate of 38% is comparable with Japan’s current screening rate for those aged 70–84 years (37.0%). Also, the 38% rate has not been achieved in some regions, such as France (34.3%, 2008–2009), the Czech Republic (22.7%, 2000–2011), Croatia (19.9%, 2007–2011) in the EU,36 and Prince Edward Island (33%), New Brunswick (30%), and Newfoundland and Labrador (20.4%) in Canada (2017).
Oncology Related Tools
- Prognostic Scoring for Myelofibrosis
- Opioid Conversion Calculator
- Updated Advanced Opioid Conversion Calculator
- Nonsteroidal anti-inflammatory drugs (NSAID) Selection Tool
- Absolute Neutrophil Count Calculator
- Body Surface Area (BSA) Multi-Calc
- Carboplatin AUC Calculator
- Carboplatin AUC – Updated Version
- Urinary Indices, Renal Failure Index (RFI) and Fractional Excretion of Sodium (FE-NA)
- Creatinine Clearance (CRCL) – Standard Calculator
- Creatinine Clearance Multi-Calc – All of the latest research
- Patient Controlled Analgesia (PCA) Settings
- Intravenous Antineoplastic Agents – Administration Guidelines
- Therapeutic Drug Levels
- Beers Criteria for potentially inappropriate medications
- Allergic response? 12-step desensitization protocol
- Protein requirements calculator
- Basal Metabolic Rate (BMR) Multi-calc (Estimate caloric requirements)
- Irritable Bowel Syndrome Treatment Options
- Common Anti-emetics
- Fall Assessment – Berg Balance Scale
- Satiation And Satiety: An Overview And Clinical Calculator
- Cholesterol Screening To Aid In Glaucoma Detection
- Hearing Screening After Chemotherapy: A Study On Childhood Cancer Survivors
- Olfactory Dysfunction and Screening For Depression: A QOL Study
- Cancer Diagnosis And Mental Health
- Mental Health Screening In Psoriatic Arthritis Patients
- Prostate Cancer: A New Biopsy Risk Calculator Using MRI
- Mental Health Study in Cancer Survivors
- Mental Health Screening In The Community
- Bone Mineral Density Screening Combined With Mammography
- Bone Mineral Density In Type 1 Diabetes Mellitus
- Cochlear Implants and Vestibular Screening
- Aprocitentan In Resistant Hypertension
- Predicting Cardiovascular Disease With Body Mass Index
- Obesity Screening To Predict Hot Flashes
- Hypertension Screening For Cardiovascular Health
- Dental Screening For Cardiovascular Disease Risk
- Blood Pressure and CVD Risk Reduction
- Lifestyle Changes For Hypoglycemia Prevention
- Ovarian Adenocarcinoma With Glaucoma: A Case Report
- Community Hypertension and Atherosclerosis Risk
- Thyroid Malignancy and Serum Calcitonin
- Rare Schwannoma In Lateral Nasal Wall
- Pyrotinib Therapy In HER2+ Breast Cancer
- Osteopenia Predicts Outcomes in Pancreatic Cancer
- Outcomes of Physical Exercise Regimens in Advanced Cancer
- Penile Squamous Cell Carcinoma And HPV
- Radiation Therapy And VTE Risk
- Pseudouveitis With Pancreatic Carcinoma: A Case Study
- Cancer Prevention In Rural Communities
- Skeletal Muscle Mass and Cancer Patient Quality of Life: A Meta-Analysis
- Incidence of Secondary Cancers After CIRT VS RT
- Filanesib Combination Therapy in Multiple Myeloma
- Pediatric Leukemia Patients Utilizing Levofloxacin
- Breast Cancer And An Analysis Of Cardiovascular Events
- Monotherapy Or Chemotherapy Adjunct: Pembrolizumab in Advanced NSCLC
- Advanced Gastric Cancer: Prognosis with Nivolumab Monotherapy
- Sinonasal B‐Cell Lymphomas A Cohort Study On Progression And Recurrence
- Platinum Resistant Recurrent Ovarian Cancer Treatment+/-Bevacizumab
- Metastatic Melanoma and Follow-Up MRI Scans
- Isatuximab Treatment in Refractory T-Acute Lymphoblastic Leukemia
- Ocular Melanoma and Treatment with Metformin
- Gastric Neuroendocrine Neoplasms
- Lung Cancer with Brain Metastasis After Late-Onset Bipolar Disorder: A Case Report
- Anlotinib with Camrelizumab in Lung Cancer Treatment
- Sebaceous Carcinoma Treatment Outcomes: A Multicenter Study
- Diffuse-Type Tenosynovial Giant Cell Tumors: Treatment and Progression
- Lung Spindle Cell Carcinoma Responsive to Pembrolizumab: A Rare Case Report
- DNA Methylation Profiling in Sarcoma Classification
- Breast Tomosynthesis Simulator For Virtual Clinical Trials
- Renal Cell Carcinoma-Prognosis Via Albumin Levels
- Diagnostic Error Causing Cases of Cytopenia
- Hodgkin’s Lymphoma: A Case Study With Nystagmus and Diplopia
- Brugada Syndrome Treated with Lenalidomide: A Case Study
- Koolen-de Vries Case Study
- Suicidal Ideation and Somatic Treatments
- Study on Pavlovian Fear Conditioning and Fear Reversal in OCD
- Anxiety Scales in Lewy Body Disease
- Inoperable Locally Advanced Non-Small Cell Lung Cancer: Survival Rates of Endostar, CCRT
- Physician Practice Management and Private Equity
- Physician Spending And Its Association With Patient Outcomes
- Physician Burnout: Causes and Prevention
- LEAP-MS: Adaptations for Advanced Stages
- MS: Exercise Impacts on MRI
- The Role of Preretirement Job Complexity in Cognitive Performance
- Extrapontine Myelinolysis and PTA in Pregnancy
- Verbal Communication and Masks
- Sugammadex Versus Neostigmine in Thyroidectomy
- SGLT Inhibitors on Weight and Lipid Metabolism in Diabetes
- Saxagliptin: Obese Patients with Impaired Glucose Tolerance
- Levothyroxine Therapy and Depression
- Grave’s Disease and Risk of Systemic Lupus Erythematosus
- Benign Thyroid Removal and Patient Satisfaction
- MF- Biology, Management, and a Case Study of Ocular Manifestation
- Quality Of Life In Adolescent Cancer Survivors
- Cancer Opioid Risk Score
- Oncology-Specific Opioid Risk Calculator In Cancer Survivors
- 3D MRI for Non-invasive Ocular Proton Therapy of Uveal Melanomas
- Sexual Dysfunction in Prostate Cancer Patients
- 3-Day Surprise Question To Predict Survival Rates in Advanced Cancer Patients